<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">305</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0352</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of <italic>MMP1</italic> and <italic>MMP3</italic> gene polymorphisms in exfoliation syndrome and exfoliation glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tsironi</surname><given-names>Evangelia E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pefkianaki</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsezou</surname><given-names>Aspasia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kotoula</surname><given-names>Maria G.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dardiotis</surname><given-names>Efthimios</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Almpanidou</surname><given-names>Pavlina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Papathanasiou</surname><given-names>Afroditi A.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rodopoulou</surname><given-names>Paraskevi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chatzoulis</surname><given-names>Dimitrios Z.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hadjigeorgiou</surname><given-names>Georgios M.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Ophthalmology, School of Medicine, University of Thessaly, Larissa, Greece</aff><aff id="aff2"><label>2</label>Department of Biology, School of Medicine, University of Thessaly, Larissa, Greece</aff><aff id="aff3"><label>3</label>Institute for Biomedical Research &#x00026; Technology (BIOMED), Centre for Research and Technology-Thessaly (CERETETH), Larissa, Greece</aff><aff id="aff4"><label>4</label>Department of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece</aff><aff id="aff5"><label>5</label>Department of Neurology, School of Medicine, University of Thessaly, Larissa, Greece</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Evangelia E. Tsironi, Department of Ophthalmology, School of Medicine, University of Thessaly, Mezourlo, Box 1400 Larissa 41110, Greece; Phone: +30 2413502793; FAX: +302410670102; email: <email xlink:href="e_tsironi@hotmail.com">e_tsironi@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>12</month><year>2009</year></pub-date><volume>15</volume><fpage>2890</fpage><lpage>2895</lpage><history><date date-type="received"><day>08</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Molecular Vision.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To investigate possible genetic associations of matrix metalloproteinase-1 (<italic>MMP1</italic>) and <italic>MMP3</italic> gene polymorphisms with exfoliation syndrome (XFS) with (XFS/+G) and without (XFS/-G) glaucoma in a cohort of Greek patients.</p></sec><sec><title>Methods</title><p>A total of 182 unrelated Greek patients with XFS, including 92 patients with XFS/+G, and 214 unrelated age- and gender-matched controls were enrolled in the study. <italic>MMP1</italic> -1607 1G/2G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1799750">rs1799750</ext-link>) and <italic>MMP3</italic> -1171 5A/6A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3025058">rs3025058</ext-link>) polymorphisms were determined using standard PCR/restriction fragment length polymorphism methods. Differences in allele and genotype distributions were analyzed using logistic regression.</p></sec><sec><title>Results</title><p>The distribution of genotypes and alleles in <italic>MMP1</italic> and <italic>MMP3</italic> polymorphisms was not significantly different between cases with exfoliation syndrome, with or without glaucoma, and controls. However, the allele contrast for the <italic>MMP1</italic> variant showed a trend for a significant association with XFS/-G (Odds Ratio=1.47 [1.03&#x02013;2.10]), since after correction for multiple comparisons, this association was no longer statistically significant.</p></sec><sec><title>Conclusions</title><p>Our study provided some evidence of a possible role of the <italic>MMP1</italic> variant in the development of exfoliation syndrome in Greek patients.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Tsironi</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Exfoliation syndrome (XFS) is an age-related generalized disorder of the extracellular matrix associated with excessive synthesis and progressive deposition of a fibrillar material in the ocular tissues as well as in the skin and connective tissue of various visceral organs [<xref ref-type="bibr" rid="r1">1</xref>]. It is characterized by small whitish deposits of fibrillar-granular material in the anterior segment of the eye. Its ocular manifestations involve all the structures of the anterior segment as well as the conjunctiva and the orbital tissues [<xref ref-type="bibr" rid="r2">2</xref>]. An increased number of associations of XFS with specific systemic disorders [<xref ref-type="bibr" rid="r1">1</xref>] has been reported.</p><p>Raised intraocular pressure develops in a significant number of patients with exfoliation syndrome. Exfoliation glaucoma (XFS/+G) is a common sight-threatening disease that develops as a consequence of exfoliation syndrome. There are important differences in the clinical appearance, course, and prognosis of exfoliative glaucoma versus primary open-angle glaucoma. On clinical, biochemical, and cellular levels, XFS/+G is a distinct entity with an intriguing mechanism of development and numerous systemic manifestations that require further elucidation [<xref ref-type="bibr" rid="r3">3</xref>].</p><p>Extracellular matrix turnover is mediated by matrix metalloproteinases (MMPs), a large family of endopeptidases with variable substrate spectra [<xref ref-type="bibr" rid="r4">4</xref>]. The activity of these enzymes is regulated in part by specific endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Complex changes in the local MMP&#x02013;TIMP are possible candidates to be involved in the abnormal extracellular matrix metabolism characteristic of XFS and XFS/+G. Increased biosynthesis of MMPs in eyes with XFS has been reported, and this may serve to degrade the abnormal fibrillar matrix components in the anterior segment tissues [<xref ref-type="bibr" rid="r5">5</xref>]. However, the increased levels of MMPs do not seem to be able to overcome the overproduction and accumulation of exfoliative material [<xref ref-type="bibr" rid="r5">5</xref>]. Growing evidence indicates that spontaneous sequence variations in the promoters of MMPs may influence critical steps in the binding of transcription factors or overall transcriptional efficiency, which results in differential expression of MMPs in different individuals [<xref ref-type="bibr" rid="r6">6</xref>].</p><p>An insertion (2G)/deletion (1G) polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1799750">rs1799750</ext-link>) of <italic>MMP1</italic> (OMIM <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120353">120353</ext-link>, chr.11q22-q23) within the promoter region at position -1607 bp influences the transcription of this <italic>MMP1</italic> gene; the 2G promoter processes greater transcriptional activity than the 1G promoter [<xref ref-type="bibr" rid="r7">7</xref>,<xref ref-type="bibr" rid="r8">8</xref>].</p><p>There is also a single adenine insertion (6A) or deletion (5A) polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3025058">rs3025058</ext-link>) at position -1171 bp of the <italic>MMP3</italic> (OMIM <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=185250">185250</ext-link>, chr.11q23) promoter that influences <italic>MMP3</italic> expression by changing the affinity of the repressor binding site, with the 6A allele sequence having a stronger recognition for the repressor binding site. This leads to enhanced transcriptional levels of <italic>MMP3</italic> in the presence of the 5A allele [<xref ref-type="bibr" rid="r6">6</xref>,<xref ref-type="bibr" rid="r9">9</xref>]. In addition, both <italic>MMP1</italic> and <italic>MMP3</italic> are known to be adjacently localized in chromosome 11q22.3, and these two loci are in linkage disequilibrium and considered to act in cooperation [<xref ref-type="bibr" rid="r10">10</xref>].</p><p>Our study was designed to investigate whether the insertion/deletion polymorphisms of the <italic>MMP1</italic> and <italic>MMP3</italic> promoters have any correlation with the development of XFS, and XFS/+G in particular. To our knowledge, this is the first study that has evaluated the association between <italic>MMP1</italic> and <italic>MMP3</italic> polymorphisms and XFS and XFS/+G.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and control subjects</title><p>This association study included 182 patients with unilateral or bilateral XFS, 92 of which had unilateral or bilateral exfoliation glaucoma (XFS/+G), 90 without glaucoma (XFS/-G), and 214 age- and gender-matched control subjects. All subjects were recruited from the Ophthalmologic Department of the University Hospital of Larissa (a tertiary referral center in central Greece that covers a population of almost one million inhabitants). The study was approved by the local ethics committee and carried out according to the Declaration of Helsinki. All subjects were of Greek nationality from the same geographic region and gave informed consent before entering the study. The age and sex distribution of the patients and controls are shown in <xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Clinical characteristics of study populations.</title></caption><table frame="hsides" rules="groups"><col width="95" span="1"/><col width="108" span="1"/><col width="94" span="1"/><col width="90" span="1"/><col width="104" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Gender/Age</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS Total (n=182)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS/+G (n=92)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS/-G (n=90)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls (n=214)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">111 (60.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58 (63.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (58.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">122 (57.0)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age&#x000b1;SD (years)</td><td valign="top" align="center" rowspan="1" colspan="1">72.0&#x000b1;7.1</td><td valign="top" align="center" rowspan="1" colspan="1">71.3&#x000b1;7.7</td><td valign="top" align="center" rowspan="1" colspan="1">72.9&#x000b1;6.1</td><td valign="top" align="center" rowspan="1" colspan="1">71.8&#x000b1;7.8</td></tr></tbody></table><table-wrap-foot><p>In the table, XFS refers to exfoliation syndrome, XFS/+G refers to exfoliation syndrome with glaucoma, and XFS/-G refers to exfoliation syndrome without glaucoma.</p></table-wrap-foot></table-wrap><p>All subjects underwent detailed ophthalmic examination by the same investigator (P.M.). Patients or controls with any type of malignancy, autoimmune disease, ocular disease, history of cardiovascular disease, neurologic disease, obstructive pulmonary disease, diabetes mellitus, hepatitis, or allergies were not included in the study because these conditions have been associated with abnormal expression of MMPs or their inhibitors [<xref ref-type="bibr" rid="r11">11</xref>].</p><p>In a detailed ophthalmologic examination, the anterior and posterior segments of all cases were evaluated, and intraocular pressures (IOPs) were measured with Goldmann applanation tonometry, manufactured by Haag-Streit (Koeniz-Berne Switzerland). The corneal endothelium, iris, iris margins, and the anterior lens surface were evaluated for exfoliative material before and after dilation. To evaluate the angle for exfoliative material and increased pigmentation, gonioprisms were used.</p><p>Patients were classified as having unilateral or bilateral XFS by the presence of characteristic fibrillar-exfoliate material on the anterior lens capsule or pupillary margin and by an open anterior chamber angle. Unilateral or bilateral XFS/+G was manifested if patients had XFS as well as an IOP greater than 22 mmHg in each eye, typical glaucomatous optic nerve changes (notching, thinner neuroretinal rim, and increased cup-to-disc ratio), and the presence of visual field defects, as determined by a Humphrey visual field analyzer, (full threshold program 24-2; Carl Zeiss Inc., Dublin, CA), consistent with the glaucomatous cupping in at least one eye. The mean IOP at diagnosis was 17&#x000b1;4 mmHg in the patients with XFS and 35.0&#x000b1;13.0 mm Hg in the patients with XFS/+G.</p><p>Control subjects had no evidence of exfoliative material at the anterior lens capsule or pupillary margin. In addition the IOP in control subjects was less than 22 mm Hg; control subjects had normal visual fields, an open anterior chamber angle, no evidence of glaucomatous changes in the optic disc, and no history of glaucoma or ocular hypertension in first-degree relatives.</p></sec><sec><title><italic>MMP1</italic> and <italic>MMP3</italic> polymorphisms</title><p>Genomic DNA was extracted from peripheral blood leukocytes using a commercially available DNA extraction kit (Qiagen, Valencia, CA), according to the manufacturer&#x02019;s instructions. Based on the sequences of <italic>MMP1 </italic>and<italic> MMP3</italic> available from GenBank and using <ext-link ext-link-type="uri" xlink:href="http://frodo.wi.mit.edu/primer3/">Primer3</ext-link> software, appropriate primers were designed for <italic>MMP1</italic> (1G/2G, -1607) and <italic>MMP3</italic> (5A/6A, -1171) polymorphisms (<xref ref-type="table" rid="t2">Table 2</xref>). Thermal cycling conditions were as follows: 15 min at 95 <sup>o</sup>C, followed by 35 cycles of 30 s at 95 <sup>o</sup>C, 30 s at 56 <sup>o</sup>C (<italic>MMP1</italic>) or 30 s at 65 <sup>o</sup>C (<italic>MMP3</italic>), 30 s at 72 <sup>o</sup>C, and with a final extension at 72 <sup>o</sup>C for 5 min. PCR products were digested for 16 h at 37 <sup>o</sup>C in a 24-&#x003bc;l reaction containing 2 &#x003bc;l AluI and 2 &#x003bc;l &#x003a4;thIII restriction enzymes for the determination of <italic>MMP1</italic> and <italic>MMP3</italic> genotypes, respectively. The digested products were subjected to gel electrophoresis and were visualized by ethidium bromide staining. The sizes of PCR products for <italic>MMP1</italic> (1G/2G, -1607) and <italic>MMP3</italic> (5A/6A, -1171) were 269 and 129 bp, respectively.</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Primer sequences for <italic>MMP1</italic> (1G/2G, -1607) and <italic>MMP3</italic> (5A/6A, -1171) polymorphisms.</title></caption><table frame="hsides" rules="groups"><col width="45" span="1"/><col width="90" span="1"/><col width="261" span="1"/><col width="252" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Gene</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Polymorphism</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Forward primer (5&#x02019;-3&#x02019;)</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Reverse primer 5&#x02019;-3&#x02019;</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><italic>MMP1</italic><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1G/2G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1799750">rs1799750</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TGACTTTTAAAACATAGTCTATGTTCA<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCTTGGATTGATTTGAGATAAGTCATAGC<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><italic>MMP3</italic></td><td valign="top" align="center" rowspan="1" colspan="1">5A/6A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3025058">rs3025058</ext-link>)</td><td valign="top" align="left" rowspan="1" colspan="1">GGTTCTCCATTCCTTTGATGGGGGGAAAGA</td><td valign="top" align="left" rowspan="1" colspan="1">CTTCCTGGAATTCACATCACTGCCACCACT</td></tr></tbody></table></table-wrap></sec><sec><title>Statistical analysis</title><p>The Hardy&#x02013;Weinberg (H-W) equilibrium [<xref ref-type="bibr" rid="r12">12</xref>] was assessed by means of an exact H-W test, implemented in the <ext-link ext-link-type="uri" xlink:href="http://www.genepop.curtin.edu.au">GENEPOP</ext-link> version 3.4 program. Power was calculated using the <ext-link ext-link-type="uri" xlink:href="http://www.sph.umich.edu/csg/abecasis/cats/">CaTS</ext-link> Power Calculator for Genetic Studies (Center for Statistical Genetics, University of Michigan, Ann Arbor, MI). Continuous variables were compared (XFS total, XFS/+G, or XFS/-G versus controls) using the nonparametric Mann&#x02013;Whitney <italic>U</italic> test, and categorical variables were compared using the &#x003c7;<sup>2</sup> test. Differences in allele and genotype distributions were analyzed using logistic regression. The odds ratio (OR) and 95% confidence interval (CI) were used as a measure of strength of association between polymorphisms and disease. In the logistic regression, the disease status (patients versus controls) was used as a dichotomous outcome, while allele or genotype was used as a predictor. We additionally controlled for potential confounders, such as age and gender. Later analyses were carried out using SPSS ver. 12.0 (SPSS, Chicago, IL). Control for multiple comparisons was performed using <ext-link ext-link-type="uri" xlink:href="http://home.clara.net/sisa/bonfer.htm">Bonferronis</ext-link> correction for two polymorphisms. The level of significance (p) was equal to 0.025 (0.05/2=0.025).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Patients and controls were in Hardy&#x02013;Weinberg equilibrium (p&#x0003e;0.05 for all groups). Differences in mean age and sex distribution between all patients and controls were not significant (p&#x0003e;0.05). Distribution of genotypes and alleles are shown in <xref ref-type="table" rid="t3">Table 3</xref>. In both polymorphisms (<italic>MMP1</italic> and <italic>MMP3</italic>), the genotype distribution of the XFS total group was not significantly different from controls (p=0.19 and p=0.99). Also, the genotype distributions of XFS/+G and XFS/-G groups were not significantly different from controls (<italic>MMP1</italic> p=0.10 and 0.70, respectively, and <italic>MMP3</italic> p=0.94 and 0.48, respectively).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Genotype and allele distribution frequencies of the <italic>MMP1</italic> -1607 polymorphism and the <italic>MMP3</italic> -1171 polymorphism.</title></caption><table frame="hsides" rules="groups"><col width="108" span="1"/><col width="68" span="1"/><col width="39" span="1"/><col width="68" span="1"/><col width="39" span="1"/><col width="65" span="1"/><col width="39" span="1"/><col width="61" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Genotypes/Alleles</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS Total (n=182)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS/+G (n=92)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>XFS/-G (n=90)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls (n=214)</bold></th></tr></thead><tbody><tr><td colspan="8" valign="top" align="left" scope="col" rowspan="1"><bold><italic>MMP-1</italic></bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2G/2G (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24 (13.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (11.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (14.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39 (18.2)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2G/1G (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89 (48.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42 (45.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47 (52.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">110 (51.4)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1G/1G (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69 (37.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39 (42.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30 (33.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.70<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65 (30.4)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1G (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">227 (62.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">120 (65.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (59.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">240 (56.1)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2G (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">137 (37.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.07<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64 (34.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.04<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">73 (40.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.44<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">188 (43.9)<hr/></td></tr><tr><td colspan="8" valign="top" align="left" scope="col" rowspan="1"><bold><italic>MMP-3</italic></bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6A/6A (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42 (23.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (27.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17 (18.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54 (25.2)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6A/5A (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">87 (47.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42 (45.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45 (50.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">101 (47.2)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">5A/5A (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (29.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (27.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.94<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (31.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.48<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59 (27.6)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">5A (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193 (53.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">92 (50.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">101 (56.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">219 (51.2)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6A (%)</td><td valign="top" align="center" rowspan="1" colspan="1">171 (47.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.99</td><td valign="top" align="center" rowspan="1" colspan="1">92 (50.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.79</td><td valign="top" align="center" rowspan="1" colspan="1">79 (43.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" rowspan="1" colspan="1">209 (48.8)</td></tr></tbody></table><table-wrap-foot><p>Genotype and allele distribution frequencies of the <italic>MMP1</italic> -1607 polymorphism and the <italic>MMP3</italic> -1171 polymorphism in the exfoliation syndrome (XFS Total), exfoliation syndrome with glaucoma (XFS/+G), exfoliation glaucoma without glaucoma (XFS/-G and control groups. The p-values for comparing each diseased group with the controls are also shown.</p></table-wrap-foot></table-wrap><p>The results of the influence of genotypes on disease susceptibility based on carrier status of risk allele and considering the allele contrast and the dominant and recessive models are shown in <xref ref-type="table" rid="t4">Table 4</xref>. The allele contrast for the <italic>MMP1</italic> variant showed a trend for a significant association for XFS/-G (1.47 [1.03&#x02013;2.10]; p=0.04). This association is considered nonsignificant after correction for multiple comparisons (level of significant &#x0003c;0.025). However, the dominant and recessive models showed that <italic>MMP1</italic> was not associated with XFS total (OR=1.51 [0.87&#x02013;2.46] and OR=0.73 [0.46&#x02013;1.13], respectively). The <italic>MMP3</italic> variant was not associated with XFS total for the allele contrast and the dominant and recessive models (OR=0.90 [0.68&#x02013;1.19]; OR=1.09 [0.68n&#x02013;1.65]; and OR=1.03 [0.66&#x02013;1.54], respectively). The subgroups XFS/+G and XFS/-G produced similar results to the XFS total for both variants.</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Influence of genotypes on disease susceptibility based on carrier status of risk allele considering dominant or recessive model.</title></caption><table frame="hsides" rules="groups"><col width="106" span="1"/><col width="44" span="1"/><col width="33" span="1"/><col width="89" span="1"/><col width="31" span="1"/><col width="43" span="1"/><col width="32" span="1"/><col width="89" span="1"/><col width="31" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Model</bold></th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1"><bold><italic>MMP-1</italic> (-1607 1G/2G)</bold></th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1"><bold><italic>MMP-3</italic> (-1171 5A/6A)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Allele contrast</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1G</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2G</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>6A</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>5A</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Controls<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">240<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">188<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">209<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">219<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/+G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">120<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.47 (1.03-2.10)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.04<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">92<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">92<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.95 (0.68-1.35)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.79<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/-G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">73<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (0.81-1.64)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.44<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">101<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.75 (0.53-1.06)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.29<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS total<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">227<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">137<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.30 (0.98-1.73)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.07<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">171<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">193<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.68-1.19)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Dominant model</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1G/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>-/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>5A/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>-/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR(95%CI)*</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Controls<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">175<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">160<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/+G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.61 (0.78-3.35)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.89 (0.50-1.53)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.68<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/-G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">77<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.33 (0.68-2.65)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.46<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">73<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.42 (0.74-2.61)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.25<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS total<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">158<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.51 (0.87-2.46)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">140<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">42<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.09 (0.68-1.65)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.91<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Recessive model</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1G/1G</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2G/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;p</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>5A/5A</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>6A/-</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95%CI)*&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;p</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Controls<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">149<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">155<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Reference<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/+G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.62 (0.43-0.98)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.05<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.04 (0.58-1.73)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.93<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS/-G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.50-1.48)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.65<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.86 (0.49-1.38)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Patients-XFS total</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">113</td><td valign="top" align="center" rowspan="1" colspan="1">0.73 (0.46-1.13)</td><td valign="top" align="center" rowspan="1" colspan="1">0.13</td><td valign="top" align="center" rowspan="1" colspan="1">53</td><td valign="top" align="center" rowspan="1" colspan="1">129</td><td valign="top" align="center" rowspan="1" colspan="1">1.03 (0.66-1.54)</td><td valign="top" align="center" rowspan="1" colspan="1">0.97</td></tr></tbody></table><table-wrap-foot><p>The asterisk indicates that OR was adjusted for age and gender.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>XFS is a complex disorder with both genetic and nongenetic factors involved in its development and progression. Among nongenetic factors, ultraviolet light, autoimmunity, slow virus infection, and trauma have been suggested as contributing factors to XFS [<xref ref-type="bibr" rid="r13">13</xref>].</p><p>Exfoliation syndrome is often clustered in families, so it has been proposed that genetic factors play an important role in its cause [<xref ref-type="bibr" rid="r14">14</xref>]. In an Icelandic twin study, five of eight monozygotic twins with exfoliation were concordant for XFS [<xref ref-type="bibr" rid="r15">15</xref>], as was the case in another small case study of monozygotic twins [<xref ref-type="bibr" rid="r14">14</xref>]. Segregation analyses conducted on the Finnish population clearly showed heredity to be a primary contributor to XFS susceptibility [<xref ref-type="bibr" rid="r14">14</xref>], and recently the susceptible loci were proposed to be 18q12.1&#x02013;21.33, 2q, 17p, and 19q.9 [<xref ref-type="bibr" rid="r16">16</xref>].</p><p>In addition, genetic association studies have been conducted to investigate the association between genetic polymorphisms and XFS with or without glaucoma. Recent studies showed that lysil oxidase-like 1 (<italic>LOX1</italic>) gene polymorphisms are highly associated with exfoliation phenotype [<xref ref-type="bibr" rid="r17">17</xref>&#x02013;<xref ref-type="bibr" rid="r20">20</xref>]. Replication studies in other populations have confirmed genetic susceptibility of <italic>LOXL1</italic> polymorphisms to XFS [<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r22">22</xref>], demonstrating that <italic>LOXL1</italic> is a major gene associated with XFS. Polymorphisms in glutathione S-transferase (<italic>GST</italic>) genes (<italic>GSTM1</italic>, <italic>GSTT1</italic>, <italic>GSTP1</italic>) [<xref ref-type="bibr" rid="r23">23</xref>] and the tumor necrosis factor-&#x003b1; gene <italic>(TNF&#x003b1;)</italic> -308 G/A have also been tested in XFS [<xref ref-type="bibr" rid="r24">24</xref>,<xref ref-type="bibr" rid="r25">25</xref>].</p><p>MMPs and their inhibitors are shown to play an important role in the development of an abnormal extracellular matrix characteristic of XFS/XFS/+G [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r26">26</xref>]. Increased biosynthesis of MMPs has been found in XFS, which may limit the progression of XFS by degrading the abnormal fibrillar matrix components in the anterior segment tissues; however, it was also suggested the MMPs may have a role in promoting exfoliation [<xref ref-type="bibr" rid="r5">5</xref>]. <italic>MMP1</italic> (1G/2G, -1607) and <italic>MMP3</italic> (5A/6A, -1171) functional polymorphisms have been studied in various diseases and in several populations [<xref ref-type="bibr" rid="r6">6</xref>]. They have been associated, among others, with increased risk for colorectal cancer [<xref ref-type="bibr" rid="r10">10</xref>], carotid artery disease [<xref ref-type="bibr" rid="r27">27</xref>], acute myocardial infarction [<xref ref-type="bibr" rid="r28">28</xref>], and idiopathic dilated cardiomyopathy [<xref ref-type="bibr" rid="r29">29</xref>].</p><p>In the present study, we determined the genotypes of two functional polymorphisms, <italic>MMP1</italic> (1G/2G, -1607) and <italic>MMP3</italic> (5A/6A, -1171), in healthy individuals and in patients with XFS and XFS/+G, and for the allele contrast we found a trend for association only between the <italic>MMP1</italic> variant and XFS without glaucoma.</p><p>We should underscore that the sample size in our study was small, and thus the power of detecting significant results was limited (almost 20%). However, candidate-gene association studies have the tendency to lack the power to detect a statistically significant association. For example, in order to achieve a power &#x0003e;80% to identify a modest genetic effect (odds ratio 1.2) of a polymorphism present in 10% of individuals, a sample size of 10,000 subjects or more would be needed [<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>]. Therefore, the sample sizes required to predict association have to be far beyond what is currently available, and no single institution or entity alone would be able to provide a reasonable number of patients. However, a future meta-analysis of multiple studies clearly has a role in offering an analysis with the potential for higher power [<xref ref-type="bibr" rid="r32">32</xref>]. Future collaborative studies may allow the pooling of data, providing more power to detect significant associations. Furthermore, consortia performing gene-candidate or genome-wide association studies will be able to replicate the validity of the present findings [<xref ref-type="bibr" rid="r33">33</xref>].</p><p>Nevertheless, the present study fulfills the minimum requirements for the association study to be informative [<xref ref-type="bibr" rid="r32">32</xref>]. These include population-based matched controls, good scientific rationale, presence of H&#x02013;W equilibrium in genotypes, and a similar ethnic background. In parallel, our study has all the limitations that are applicable to genetic association studies [<xref ref-type="bibr" rid="r34">34</xref>]. Because our hospital is the only tertiary institution covering a rural and urban region with nearly 1 million inhabitants, patients included in this study are population-based XFS patients. For this reason, more severe patients are usually referred to our hospital, and we cannot exclude the possibility that a selection bias may have occurred.</p><p>In summary, our study provided some evidence of a possible significant role of the <italic>MMP1</italic> variant in the development of exfoliation syndrome in Greek patients. However, as we cannot exclude the possibility that our findings were due to random events or type 1 error, further studies using large cohorts of patients are needed to explore the possible genetic involvement of the above polymorphisms in the exfoliation syndrome.</p></sec></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Naumann</surname><given-names>GO</given-names></name></person-group><article-title>Ocular and systemic pseudoexfoliation syndrome.</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>921</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16678509</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name></person-group><article-title>Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Proceedings of the First International Think Tank.</article-title><source>Acta Ophthalmol Scand</source><year>2001</year><volume>79</volume><fpage>213</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11284770</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstas</surname><given-names>AG</given-names></name><name><surname>Tsironi</surname><given-names>S</given-names></name><name><surname>Ritch</surname><given-names>R</given-names></name></person-group><article-title>Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma.</article-title><source>Compr Ophthalmol Update</source><year>2006</year><volume>7</volume><fpage>131</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16882401</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Woessner</surname><given-names>JF</given-names><suffix>Jr</suffix></name></person-group><article-title>Matrix metalloproteinases.</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>21491</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10419448</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gartaganis</surname><given-names>SP</given-names></name><name><surname>Georgakopoulos</surname><given-names>CD</given-names></name><name><surname>Mela</surname><given-names>EK</given-names></name><name><surname>Exarchou</surname><given-names>A</given-names></name><name><surname>Ziouti</surname><given-names>N</given-names></name><name><surname>Assouti</surname><given-names>M</given-names></name><name><surname>Vynios</surname><given-names>DH</given-names></name></person-group><article-title>Matrix metalloproteinases and their inhibitors in exfoliation syndrome.</article-title><source>Ophthalmic Res</source><year>2002</year><volume>34</volume><fpage>165</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12097800</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name></person-group><article-title>Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.</article-title><source>Matrix Biol</source><year>2000</year><volume>19</volume><fpage>623</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11102751</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joos</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Shepherdson</surname><given-names>MB</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Pare</surname><given-names>PD</given-names></name><name><surname>Sandford</surname><given-names>AJ</given-names></name></person-group><article-title>The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function.</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11875051</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titeux</surname><given-names>M</given-names></name><name><surname>Pendaries</surname><given-names>V</given-names></name><name><surname>Tonasso</surname><given-names>L</given-names></name><name><surname>Decha</surname><given-names>A</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Hovnanian</surname><given-names>A</given-names></name></person-group><article-title>A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa.</article-title><source>Hum Mutat</source><year>2008</year><volume>29</volume><fpage>267</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">18030675</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Kurkinen</surname><given-names>M</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Henney</surname><given-names>AM</given-names></name></person-group><article-title>Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>13055</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8662692</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Okayama</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>N</given-names></name><name><surname>Fujimura</surname><given-names>K</given-names></name><name><surname>Suehiro</surname><given-names>Y</given-names></name><name><surname>Hamanaka</surname><given-names>Y</given-names></name><name><surname>Hazama</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name></person-group><article-title>Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer.</article-title><source>Int J Cancer</source><year>2002</year><volume>102</volume><fpage>526</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12432557</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Lommatzsch</surname><given-names>J</given-names></name><name><surname>Kuchle</surname><given-names>M</given-names></name><name><surname>Konstas</surname><given-names>AG</given-names></name><name><surname>Naumann</surname><given-names>GO</given-names></name></person-group><article-title>Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>1117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">12601038</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjigeorgiou</surname><given-names>GM</given-names></name><name><surname>Stefanidis</surname><given-names>I</given-names></name><name><surname>Dardiotis</surname><given-names>E</given-names></name><name><surname>Aggellakis</surname><given-names>K</given-names></name><name><surname>Sakkas</surname><given-names>GK</given-names></name><name><surname>Xiromerisiou</surname><given-names>G</given-names></name><name><surname>Konitsiotis</surname><given-names>S</given-names></name><name><surname>Paterakis</surname><given-names>K</given-names></name><name><surname>Poultsidi</surname><given-names>A</given-names></name><name><surname>Tsimourtou</surname><given-names>V</given-names></name><name><surname>Ralli</surname><given-names>S</given-names></name><name><surname>Gourgoulianis</surname><given-names>K</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name></person-group><article-title>Low RLS prevalence and awareness in central Greece: an epidemiological survey.</article-title><source>Eur J Neurol</source><year>2007</year><volume>14</volume><fpage>1275</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17956448</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsius</surname><given-names>H</given-names></name><name><surname>Forsman</surname><given-names>E</given-names></name><name><surname>Fellman</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>AW</given-names></name></person-group><article-title>Exfoliation syndrome: frequency, gender distribution and association with climatically induced alterations of the cornea and conjunctiva.</article-title><source>Acta Ophthalmol Scand</source><year>2002</year><volume>80</volume><fpage>478</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">12390157</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsman</surname><given-names>E</given-names></name><name><surname>Cantor</surname><given-names>RM</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>A</given-names></name><name><surname>Fellman</surname><given-names>J</given-names></name><name><surname>Jarvela</surname><given-names>I</given-names></name><name><surname>Forsius</surname><given-names>H</given-names></name></person-group><article-title>Exfoliation syndrome: prevalence and inheritance in a subisolate of the Finnish population.</article-title><source>Acta Ophthalmol Scand</source><year>2007</year><volume>85</volume><fpage>500</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17655611</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottfredsdottir</surname><given-names>MS</given-names></name><name><surname>Sverrisson</surname><given-names>T</given-names></name><name><surname>Musch</surname><given-names>DC</given-names></name><name><surname>Stefansson</surname><given-names>E</given-names></name></person-group><article-title>Chronic open-angle glaucoma and associated ophthalmic findings in monozygotic twins and their spouses in Iceland.</article-title><source>J Glaucoma</source><year>1999</year><volume>8</volume><fpage>134</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10209731</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmela</surname><given-names>S</given-names></name><name><surname>Forsman</surname><given-names>E</given-names></name><name><surname>Sistonen</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>A</given-names></name><name><surname>Forsius</surname><given-names>H</given-names></name><name><surname>Jarvela</surname><given-names>I</given-names></name></person-group><article-title>Genome-wide scan of exfoliation syndrome.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>4136</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17724198</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Magnusson</surname><given-names>KP</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Walters</surname><given-names>GB</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Stefansdottir</surname><given-names>G</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Hardarson</surname><given-names>GA</given-names></name><name><surname>Petursson</surname><given-names>H</given-names></name><name><surname>Arnarsson</surname><given-names>A</given-names></name><name><surname>Motallebipour</surname><given-names>M</given-names></name><name><surname>Wallerman</surname><given-names>O</given-names></name><name><surname>Wadelius</surname><given-names>C</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Jonasson</surname><given-names>F</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>1397</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">17690259</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasutto</surname><given-names>F</given-names></name><name><surname>Krumbiegel</surname><given-names>M</given-names></name><name><surname>Mardin</surname><given-names>CY</given-names></name><name><surname>Paoli</surname><given-names>D</given-names></name><name><surname>Lammer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BH</given-names></name><name><surname>Kruse</surname><given-names>FE</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name></person-group><article-title>Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>1459</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18385063</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Vithana</surname><given-names>EN</given-names></name><name><surname>Yong</surname><given-names>VH</given-names></name><name><surname>Thalamuthu</surname><given-names>A</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Venkatraman</surname><given-names>A</given-names></name><name><surname>Aung</surname><given-names>T</given-names></name></person-group><article-title>Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>3976</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18450598</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challa</surname><given-names>P</given-names></name></person-group><article-title>Genetics of pseudoexfoliation syndrome.</article-title><source>Curr Opin Ophthalmol</source><year>2009</year><volume>20</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">19240540</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Gramer</surname><given-names>E</given-names></name><name><surname>Muller-Myhsok</surname><given-names>B</given-names></name><name><surname>Pasutto</surname><given-names>F</given-names></name><name><surname>Gramer</surname><given-names>G</given-names></name><name><surname>Wissinger</surname><given-names>B</given-names></name><name><surname>Weisschuh</surname><given-names>N.</given-names></name></person-group><article-title>Lysyl Oxidase-like 1 Gene Polymorphisms in German Patients With Normal Tension Glaucoma, Pigmentary Glaucoma and Exfoliation Glaucoma.</article-title><source>J Glaucoma</source><year>2009</year><pub-id pub-id-type="pmid">19373106</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramprasad</surname><given-names>VL</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Soumittra</surname><given-names>N</given-names></name><name><surname>Sharmila</surname><given-names>F</given-names></name><name><surname>Vijaya</surname><given-names>L</given-names></name><name><surname>Kumaramanickavel</surname><given-names>G</given-names></name></person-group><article-title>Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>318</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18334947</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>A</given-names></name><name><surname>Tamer</surname><given-names>L</given-names></name><name><surname>Ates</surname><given-names>NA</given-names></name><name><surname>Yildirim</surname><given-names>O</given-names></name><name><surname>Yildirim</surname><given-names>H</given-names></name><name><surname>Atik</surname><given-names>U</given-names></name></person-group><article-title>Is GST gene polymorphism a risk factor in developing exfoliation syndrome?</article-title><source>Curr Eye Res</source><year>2005</year><volume>30</volume><fpage>575</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16020292</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekeli</surname><given-names>O</given-names></name><name><surname>Turacli</surname><given-names>ME</given-names></name><name><surname>Egin</surname><given-names>Y</given-names></name><name><surname>Akar</surname><given-names>N</given-names></name><name><surname>Elhan</surname><given-names>AH</given-names></name></person-group><article-title>Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>1815</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18852869</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossbock</surname><given-names>G</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Faschinger</surname><given-names>C</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Wedrich</surname><given-names>A</given-names></name><name><surname>Zimmermann</surname><given-names>C</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name></person-group><article-title>TNF-alpha -308 G&#x0003e;A and -238 G&#x0003e;A polymorphisms are not major risk factors in Caucasian patients with exfoliation glaucoma.</article-title><source>Mol Vis</source><year>2009</year><volume>15</volume><fpage>518</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19279689</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name></person-group><article-title>Exfoliation syndrome.</article-title><source>Surv Ophthalmol</source><year>2001</year><volume>45</volume><fpage>265</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">11166342</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghilardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>ML</given-names></name><name><surname>DeMonti</surname><given-names>M</given-names></name><name><surname>Turri</surname><given-names>O</given-names></name><name><surname>Guagnellini</surname><given-names>E</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group><article-title>Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis.</article-title><source>Stroke</source><year>2002</year><volume>33</volume><fpage>2408</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12364729</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terashima</surname><given-names>M</given-names></name><name><surname>Akita</surname><given-names>H</given-names></name><name><surname>Kanazawa</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Takai</surname><given-names>E</given-names></name><name><surname>Iwai</surname><given-names>C</given-names></name><name><surname>Kurogane</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name></person-group><article-title>Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction.</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>2717</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10351963</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>LJ</given-names></name><name><surname>Chen</surname><given-names>XF</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>JJ</given-names></name><name><surname>Lu</surname><given-names>XB</given-names></name><name><surname>Du</surname><given-names>YX</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>CF</given-names></name><name><surname>Xue</surname><given-names>YS</given-names></name><name><surname>Shen</surname><given-names>WF</given-names></name></person-group><article-title>Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population.</article-title><source>Clin Biochem</source><year>2007</year><volume>40</volume><fpage>1427</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18028894</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Trends in meta-analysis of genetic association studies.</article-title><source>J Hum Genet</source><year>2008</year><volume>53</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18071627</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches.</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>634</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">18538260</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitsios</surname><given-names>GD</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name></person-group><article-title>Genomic convergence of genome-wide investigations for complex traits.</article-title><source>Ann Hum Genet</source><year>2009</year><volume>73</volume><fpage>514</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19604225</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitsios</surname><given-names>GD</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name></person-group><article-title>Genome-wide association studies: hypothesis-"free" or "engaged"?</article-title><source>Transl Res</source><year>2009</year><volume>154</volume><fpage>161</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">19766959</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name></person-group><article-title>Association study designs for complex diseases.</article-title><source>Nat Rev Genet</source><year>2001</year><volume>2</volume><fpage>91</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11253062</pub-id></mixed-citation></ref></ref-list></back></article>